Camrelizumab
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-CAMRELIZUMAB |
|---|---|
| Type | Médicament |
| Alias | AiRuiKaSHR-1210Камрелізумаб |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | DIS-NPC |
| Sources | SRC-CAPTAIN-1ST-YANG-2021 |
Faits sur les drogues
| Catégorie | Anticorps monoclonal IgG4 humanisé anti-PD-1 (inhibiteur du point de contrôle immunitaire) |
|---|---|
| Mécanisme | Humanized IgG4 monoclonal antibody binding PD-1 on activated T cells, blocking PD-1/PD-L1 and PD-1/PD-L2 interactions and restoring cytotoxic T-cell antitumor activity. Same general anti-PD-1 mechanistic class as pembrolizumab, nivolumab, and toripalimab. Studied specifically in recurrent/metastatic nasopharyngeal carcinoma (CAPTAIN-1st) combined with gemcitabine + cisplatin, as well as in multiple other Chinese-registered indications (hepatocellular carcinoma, NSCLC, esophageal SCC, classical Hodgkin lymphoma). |
| Dose typique | Per the CAPTAIN-1st trial protocol: camrelizumab 200 mg IV every 3 weeks, combined with gemcitabine + cisplatin (GP) for up to 6 cycles, followed by camrelizumab monotherapy (200 mg IV q3w) until disease progression, unacceptable toxicity, or up to 2 years total. STUB — dosing drafted from trial-protocol recall; pending Clinical Co-Lead confirmation against the primary source. |
| Ukraine enregistrée | Faux |
| NSZU remboursé | Faux |
Notes
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; currently dev-mode-exempted). Anti-PD-1 backbone alternative for NPC metastatic 1L combination per CAPTAIN-1st (Yang Y et al., Lancet Oncol 2021): camrelizumab + gemcitabine + cisplatin significantly improved PFS vs chemo alone in treatment-naive recurrent/metastatic NPC. NOT FDA-approved (China/NMPA-approved only) — distinguishes it from toripalimab (DRUG-TORIPALIMAB), the FDA-approved alternative for the identical clinical scenario. Reuse this entity rather than duplicate. RCCEP is a genuinely distinctive camrelizumab-class AE not shared with pembrolizumab/nivolumab/toripalimab — worth flagging for patient counseling.
Utilisé par
Médicament
DRUG-TORIPALIMAB- Toripalimab
Protocole thérapeutique
REG-NPC-GC-CAMRELIZUMAB- Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L recurrent/metastatic nasopharyn...